PMC:7652766 / 80518-80770 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T394","span":{"begin":0,"end":252},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A randomized phase I/II trial studied the infusions of CYNK-001 cells, an allogeneic off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells in 86 hospitalized patients with moderate COVID-19 disease (283)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2908","span":{"begin":125,"end":129},"obj":"Gene"},{"id":"2909","span":{"begin":175,"end":179},"obj":"Gene"},{"id":"2917","span":{"begin":159,"end":164},"obj":"Species"},{"id":"2918","span":{"begin":206,"end":214},"obj":"Species"},{"id":"2921","span":{"begin":0,"end":1},"obj":"Gene"},{"id":"2922","span":{"begin":229,"end":237},"obj":"Disease"}],"attributes":[{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"Gene:4684"},{"id":"A2909","pred":"tao:has_database_id","subj":"2909","obj":"Gene:947"},{"id":"A2917","pred":"tao:has_database_id","subj":"2917","obj":"Tax:9606"},{"id":"A2918","pred":"tao:has_database_id","subj":"2918","obj":"Tax:9606"},{"id":"A2921","pred":"tao:has_database_id","subj":"2921","obj":"Gene:351"},{"id":"A2922","pred":"tao:has_database_id","subj":"2922","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A randomized phase I/II trial studied the infusions of CYNK-001 cells, an allogeneic off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells in 86 hospitalized patients with moderate COVID-19 disease (283)."}